The effect of SARS-CoV-2 vaccination on post-acute COVID-19 syndrome (PASC): A prospective cohort study 8 251 compared to those who did not (0.324 [95%CrI 0.091-0.549]; Figure 3), yet no difference in neutralising IgG levels was observed (0.147 [95%CrI -0.113-0.450]). Figure 3. IgG binding and spike neutralisation at 30–60 days following illness onset among participants with mild COVID-19 who did (N = 16) and did not (N = 36) develop PASC Difference in 30–60 day WT-D614G spike protein neutralising IgG titers and anti-spike and anti-RBD IgG binding titers between those who did and did not develop PASC with mild COVID-19. The mean effects on neutralising and IgG titers from those who did and did not develop PASC were estimated using a Bayesian multilevel model. Differences in posterior means were mean-centred such that effect sizes shown can be compared on a common scale (top row). Distributions of serum spike protein neutralising IgG titers (bottom left), spike binding (bottom middle) and RBD binding (bottom right) displayed such that each dot represents one participant. RBD = Receptor binding domain. PASC = Post-acute sequelae of COVID-19. Association between PASC and antibody decay over time The estimated median half-life of spike- and RBD-binding IgG levels appeared to be slightly greater for participants with PASC at 3 months after illness onset, however, 95%CrI were largely overlapping for both spike- and RBD-binding IgG titers (Figure 4) and therefore this difference was not statistically significant.
RkJQdWJsaXNoZXIy MTk4NDMw